3-乙氧基-联苯-4-羧酸 | 202208-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-乙氧基-联苯-4-羧酸
• 英文名称: 3'‐ethoxy‐(1,1'‐biphenyl)‐4‐carboxylic acid
• 英文别名: 4-(3-ethoxyphenyl)benzoic acid
• CAS: 202208-73-9
• 化学式: C₁₅H₁₄O₃
• mdl: MFCD03426474
• 分子量: 242.274
• InChiKey: XPDQGPUCKPVYNI-UHFFFAOYSA-N

物化性质

• 沸点：
  409.9±28.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-乙氧基-联苯-4-羧酸 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 sodium hydroxide 、 molecular sieve 、 草酰氯 、 硫化氢 、 ammonium acetate 、 三乙胺 、 N,N-二甲基甲酰胺 、 碘甲烷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.67h， 生成 (E)-(2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[(3'-ethoxy-biphenyl-4-carbonyl)-amino]-5-phenyl-pent-4-enoic acid methyl ester
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y
• 作为产物：
  描述：

  3-溴苯乙醚 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium hydroxide 、 正丁基锂 、 二异丁基氢化铝 、 zinc(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 3-乙氧基-联苯-4-羧酸
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y

文献信息

• Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
  申请人：Sharma Rajiv

  公开号：US20070244155A1

  公开（公告）日：2007-10-18

  Compounds having the general formula I and/or the general formula II are useful, for example, for treating metabolic disorders in a subject where the variables are provided herein. Compositions and methods for using the compounds for preparing medicaments and for treating metabolic disorders such as, for instance, type II diabetes are disclosed.

  具有一般式I和/或一般式II的化合物可用于治疗受试者的代谢性疾病，其中变量在此处提供。本文揭示了使用这些化合物制备药物和治疗代谢性疾病（例如2型糖尿病）的组合物和方法。
• WO2007/106469
  申请人：——

  公开号：——

  公开（公告）日：——
• A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences
  作者：Julius Pollinger、Simone Schierle、Leonie Gellrich、Julia Ohrndorf、Astrid Kaiser、Pascal Heitel、Apirat Chaikuad、Stefan Knapp、Daniel Merk

  DOI：10.1021/acsmedchemlett.9b00306

  日期：2019.9.12

  The nuclear retinoid X receptors (RXRs) are key ligand sensing transcription factors that serve as universal nuclear receptor heterodimer partners and are thus involved in numerous physiological processes. Therapeutic targeting of RXRs holds high potential but available RXR activators suffer from limited safety. Selectivity for RXR subtypes or for certain RXR heterodimers are promising strategies for safer RXR modulation. Here, we report systematic structure activity relationship studies on biphenyl carboxylates as new RXR ligand chemotype. We discovered specific structural modifications that enhance potency on RXRs, govern subtype preference, and vary modulation of different RXR heterodimers. Fusion of these structural motifs enabled specific tuning of subtype preferential profiles with markedly improved potency. Our results provide further evidence that RXR subtype selective ligands can be designed and present a novel chemotype of RXR modulators that can be tuned for subtype and heterodimer preferences.
• BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS
  申请人：Amgen, Inc

  公开号：EP2001844A2

  公开（公告）日：2008-12-17
• [EN] BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS<br/>[FR] DERIVES BICYCLIQUES DE L'ACIDE CARBOXYLIQUE UTILES DANS LE TRAITEMENT DE TROUBLES METABOLIQUES
  申请人：AMGEN INC

  公开号：WO2007106469A2

  公开（公告）日：2007-09-20

  [EN] Compounds having the general formula I and/or the general formula II are useful, for example, for treating metabolic disorders in a subject formula (I) (II) where the variables are provided herein. Compositions and methods for using the compounds for preparing medicaments and for treating metabolic disorders such as, for instance, type II diabetes are disclosed.
  [FR] Composés de formule générale I et/ou de formule générale II, utiles, par exemple, dans le traitement de troubles métaboliques chez un sujet. Compositions et procédés d'utilisation des composés pour la préparation des médicaments et pour le traitement de troubles métaboliques tels que le diabète de type II.